Study design and study participants
hair loss, alopecia, hypersensitivity, FAGA
HAIR LOSS, ALOPECIA, HYPERSENSITIVITY, CARDIOVASCULAR DISEASE
This was a 24-week, double-blind (patient and outcome assessors), randomized, controlled, parallel study. Sixty-six patients were recruited from the Dermatology Clinic, Cairo University Teaching Hospital (Kasr- Al- Ainy), Egypt, after obtaining their written consent and after the approval of the Research Ethics Committee for Experimental and Clinical Studies, Faculty of Pharmacy, Cairo University (CL 2555). The study was registered in clinicaltrials.gov, identifier number NCT04481412.The inclusion criteria were: FAGA patients aged 20 to 50 years, experiencing active hair loss within the last year, Sinclair grade of II-IV, willing to continue their current regimen of vitamins and not start any new vitamins and to use a mild non-medicated shampoo and conditioner during the study, did not receive any topical or systemic treatment for AGA or PGs in the last 6 months. The exclusion criteria were: patients with other chronic dermatological conditions, hair transplants, scalp reduction, current hair weave or tattooing in the target area, received radiation therapy to the scalp, or had chemotherapy in the past year, had a known underlying medical problem that could influence hair growth, with clinical diagnosis of non-AGA forms of alopecia, pregnant or lactating females or planning to become pregnant during the study, with severe cardiovascular disease, with hair loss for greater than 5 years, with known hypersensitivity to any of the treatments components, using medications that induce hair loss within the last 3 months and any patients refusing to participate.